146.63
+3.63(+2.54%)
Currency In USD
| Previous Close | 143 |
| Open | 143.29 |
| Day High | 147.47 |
| Day Low | 142.41 |
| 52-Week High | 190.4 |
| 52-Week Low | 110.04 |
| Volume | 1.23M |
| Average Volume | 1.61M |
| Market Cap | 21.5B |
| PE | 14.03 |
| EPS | 10.45 |
| Moving Average 50 Days | 141.5 |
| Moving Average 200 Days | 135.24 |
| Change | 3.63 |
If you invested $1000 in Biogen Inc. (BIIB) 10 years ago, it would be worth $551.63 as of October 20, 2025 at a share price of $146.63. Whereas If you bought $1000 worth of Biogen Inc. (BIIB) shares 5 years ago, it would be worth $548.93 as of October 20, 2025 at a share price of $146.63.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Biogen and Stoke Therapeutics Present New Data at the 54th Child Neurology Society (CNS) Annual Meeting that Support the Potential of Zorevunersen as a Disease-Modifying Medicine for Dravet Syndrome
GlobeNewswire Inc.
Oct 09, 2025 8:30 PM GMT
– An analysis designed to evaluate the potential effects of the Phase 3 zorevunersen dosing regimen showed continuing improvements in cognition and behavior at 2 years; results contrast with minimal change in natural history – – Improvements in overa
“LEQEMBI®” (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Approved in China
GlobeNewswire Inc.
Sep 28, 2025 11:30 PM GMT
TOKYO and CAMBRIDGE, Mass., Sept. 28, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen
LEQEMBI® (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in Australia
GlobeNewswire Inc.
Sep 24, 2025 11:30 AM GMT
TOKYO and CAMBRIDGE, Mass., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen